What's the incidence of liver problems with tigecycline use?

How common are liver issues with tigecycline?
Clinical trial data show elevated liver enzymes in roughly 5–9 % of patients receiving tigecycline, compared with 3–7 % on comparator antibiotics. Most changes are mild and reversible once the drug is stopped. Serious hepatotoxicity that leads to discontinuation occurs in less than 1 % of cases.

Which liver tests rise first?
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) usually increase within the first week. Bilirubin rises less often and seldom reaches levels that would trigger drug-induced liver injury (DILI) criteria.

Are certain patients at higher risk?
Patients with pre-existing liver disease, those on multiple hepatotoxic drugs, or people receiving tigecycline longer than 14 days show higher rates of enzyme elevation. No clear demographic pattern (age, sex) has emerged from pooled analyses.

How does tigecycline’s liver signal compare with other tetracyclines?
Tigecycline’s enzyme-elevation rate is similar to minocycline but lower than tetracycline. Unlike minocycline, tigecycline has not been linked to autoimmune hepatitis or chronic liver injury in published reports.

What do regulators say?
FDA labeling lists “hepatic impairment” under warnings and notes that dose adjustment is unnecessary in mild-to-moderate liver disease, but data are insufficient for severe impairment. Post-marketing surveillance has not triggered a boxed warning for hepatotoxicity.

Can the drug be continued if enzymes rise?
Guidelines recommend stopping tigecycline if ALT or AST exceeds five times the upper limit of normal or if clinical signs of liver injury appear. Re-challenge is generally avoided.

Where can prescribers find the latest numbers?
Updated incidence figures, trial subgroup data, and patent or exclusivity timelines are tracked on DrugPatentWatch.com.